title: Comparison of the Renoprotective Effect of Febuxostat for the Treatment of Hyperuricemia between Patients with and without Type 2 Diabetes Mellitus: A Retrospective Observational Study.
abstract: Objective The effects of febuxostat therapy on hyperuricemia in patients with and without type 2 diabetes were compared in this retrospective observational study after pair-matching using the propensity scores. Methods In total, 160 patients with hyperuricemia were studied as the treated set, and the 155 subjects in whom the administration of febuxostat was not discontinued during the observation period were investigated in the full analysis. The study subjects were divided into two groups based on the style of initiation of febuxostat: initial and switching therapy from allopurinol administration. Results The reduction in the serum uric acid (sUA) levels at six months after the initiation of febuxostat administration did not significantly differ between the patients with and without diabetes in both the initial (206±114 and 226±113 μmol/L in patients with and without diabetes, respectively) and switching (154±91 and 129±90 μmol/L in patients with and without diabetes, respectively) therapy groups. The eGFR values were significantly increased compared to the baseline levels only in the patients without diabetes. The changes in the eGFR values were significantly associated with the presence of diabetes and sUA at baseline in a multivariate analysis. The frequency of adverse events was not significantly different between the patients with and without diabetes. Conclusion Although febuxostat exerted a similar sUA-lowering effect against hyperuricemia in patients with type 2 diabetes compared to those without, the renoprotective effect was attenuated in those with diabetes compared to nondiabetic subjects.
authors.affiliation: Department of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Ito
authors.forename: Shinichi
authors.initials: S
authors.lastname: Antoku
authors.forename: Mariko
authors.initials: M
authors.lastname: Abe
authors.forename: Takashi
authors.initials: T
authors.lastname: Omoto
authors.forename: Masahiro
authors.initials: M
authors.lastname: Shinozaki
authors.forename: Shinya
authors.initials: S
authors.lastname: Nishio
authors.forename: Mizuo
authors.initials: M
authors.lastname: Mifune
authors.forename: Michiko
authors.initials: M
authors.lastname: Togane
authors.forename: Masaya
authors.initials: M
authors.lastname: Nakata
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Yamashita
mesh_terms: D000328:Adult; D000493:Allopurinol / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D000069465:Febuxostat / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D033461:Hyperuricemia / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D014527:Uric Acid / Q000097:blood; D014968:Xanthine Dehydrogenase / Q000037:antagonists & inhibitors*
chemical_list: D004791:Enzyme Inhibitors; D000069465:Febuxostat; D014527:Uric Acid; D000493:Allopurinol; D014968:Xanthine Dehydrogenase